ArticleBiotechnology letters2026
Recombinant AflQ: a novel fungal-derived protein with potent antibacterial properties.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycotoxins, especially aflatoxins produced by fungi of the genus Aspergillus, threaten global food security and public health due to their carcinogenic and immunosuppressive effects. To exploit Key enzymatic steps in the aflatoxin biosynthetic pathway for therapeutic applications, the aflQ gene (also Known ordA) -wich encodes acytochrome P450 monooxygenase capable of generating reactive oxidative species -was targeted as a candidate antimicrobial agent. This study aims to extract and characterize the aflQ gene (known as ordA) from the Aspergillus niger fungus isolated from grain silos in Anbar Governorate, ands proteomically evaluate it as an innovative antimicrobial. The methodology involved isolating the fungus and molecularly characterizing it by amplifying and sequencing a segment ofthe18S rRNA gene. The species identity was confirmed utilizing the BLAST tool in the NCBI database. The sequence was deposited in GenBank and received an Accession number (PV455323). Subsequently, amplification of the aflQ gene was performed using polymerase chain reaction (PCR) and cloned into the pET-30b( +) expression vector. The hybrid plasmid was transformed into E. coli BL21 bacteria, and gene expression was induced using IPTG. The protein production was confirmed by SDS-PAGE analysis at the predicted molecular weight of 63-64 kDa. The results showed that the recombinant AflQ protein exhibited significantly enhanced inhibitory potency, with inhibition diameters reaching 24 mm against Gram-positive bacteria (Staphylococcus and Enterococcus) and 12.5 mm against Gram-negative bacteria (E. coli and K. pneumoniae). Conversely, the control bacterial culture showed no inhibitory activity, verifying that the observed efficacy specific to the AflQ protein. The study concludes that the AflQ protein represents a new class of oxidoreductase/Cytochrome P450antimicrobial agents. It highlights the significance of utilizing cellular debris to reduce industrial production costs by eliminating expensive purification steps.
Indexed as
Identifiers
42700274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.